Advertisement

Molecular Medicine

, Volume 21, Issue 1, pp 924–936 | Cite as

Cryopreserved Interleukin-4-Treated Macrophages Attenuate Murine Colitis in an Integrin β7-Dependent Manner

  • Gabriella Leung
  • Björn Petri
  • José Luis Reyes
  • Arthur Wang
  • Jordan Iannuzzi
  • Derek M. McKay
Research Article

Abstract

The adoptive transfer of alternatively activated macrophages (AAMs) has proven to attenuate inflammation in multiple mouse models of colitis; however, the effect of cryopreservation on AAMs, the ability of previously frozen AAMs to block dinitrobenzene sulfonic acid (DNBS) (Th1) and oxazolone (Th2) colitis and their migration postinjection remains unknown. Here we have found that while cryopreservation reduced mRNA expression of canonical markers of interleukin (IL)-4-treated macrophages [M(IL-4)], this step did not translate to reduced protein or activity, and the cells retained their capacity to drive the suppression of colitis. The anticolitic effect of M(IL-4) adoptive transfer required neither T or B cell nor peritoneal macrophages in the recipient. After injection into the peritoneal cavity, M(IL-4)s migrated to the spleen, mesenteric lymph nodes and colon of DNBS-treated mice. The chemokines CCL2, CCL4 and CX3CL1 were expressed in the colon during the course of DNBS-induced colitis. The expression of integrin β7 on transferred M(IL-4)s was required for their anticolitic effect, whereas the presence of the chemokine receptors CCR2 and CX3CR1 were dispensable in this model. Collectively, the data show that M(IL-4)s can be cryopreserved M(IL-4)s and subsequently used to suppress colitis in an integrin β7-dependent manner, and we suggest that these proof-of-concept studies may lead to new cellular therapies for human inflammatory bowel disease.

Notes

Acknowledgments

The authors would like to thank Michael Dicay and Evelyn Lailey for their phlebotomy assistance. This work was supported by the Mouse Phenomics Resources Laboratory and Live Cell Imaging Facility, both of which were funded by the Snyder Institute at the University of Calgary. This research is funded by the following: Crohn’s and Colitis Canada operating grant (to DM McKay), Alberta Innovates Health Solutions (AIHS) Scientist Award (to DM McKay), Canada Research Chair (Tier 1) in Intestinal Immunophysiology Award (DM McKay), AIHS Fellowship (to JL Reyes), an AIHS Summer Studentship (to J Iannuzzi) and an AIHS Doctoral Studentship (to G Leung).

Supplementary material

10020_2015_2101924_MOESM1_ESM.pdf (3.8 mb)
Supplementary material, approximately 3.78 MB.

References

  1. 1.
    Palucka K, Banchereau J. (2013) Dendritic-cell-based therapeutic cancer vaccines. Immunity. 39:38–48.CrossRefGoogle Scholar
  2. 2.
    Restifo NP, Dudley ME, Rosenberg SA. (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12:269–81.CrossRefGoogle Scholar
  3. 3.
    Mothe AJ, Tator CH. (2012) Advances in stem cell therapy for spinal cord injury. J. Clin. Invest. 122:3824–34.CrossRefGoogle Scholar
  4. 4.
    Gazouli M, Roubelakis MG, Theodoropoulos GE. (2014) Stem cells as potential targeted therapy for inflammatory bowel disease. Inflamm. Bowel Dis. 20:952–5.CrossRefGoogle Scholar
  5. 5.
    van Deen WK, Oikonomopoulos A, Hommes DW. (2013) Stem cell therapy in inflammatory bowel disease: which, when and how? Curr. Opin. Gastroenterol. 29:384–90.CrossRefGoogle Scholar
  6. 6.
    Desreumaux P, et al. (2012) Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn’s disease. Gastroenterology. 143:1207–17.e1202.CrossRefGoogle Scholar
  7. 7.
    Loke Pn, Allison JP. (2003) PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. U. S. A. 100:5336–41.CrossRefGoogle Scholar
  8. 8.
    Huber S, Hoffmann R, Muskens F, Voehringer D. (2010) Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2. Blood. 116:3311–20.CrossRefGoogle Scholar
  9. 9.
    Stein M, Keshav S, Harris N, Gordon S. (1992) Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 176:287–92.CrossRefGoogle Scholar
  10. 10.
    Pesce JT, et al. (2009) Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog. 5:e1000371.CrossRefGoogle Scholar
  11. 11.
    Song E, et al. (2000) Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol. 204:19–28.CrossRefGoogle Scholar
  12. 12.
    McKay DM. (2009) The therapeutic helminth? Trends Parasitol. 25:109–14.CrossRefGoogle Scholar
  13. 13.
    Martinez FO, Gordon S. (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6:6–13.CrossRefGoogle Scholar
  14. 14.
    Hunter MM, et al. (2010) In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology. 138:1395–405.CrossRefGoogle Scholar
  15. 15.
    Weisser SB, et al. (2011) SHIP-deficient, alternatively activated macrophages protect mice during DSS-induced colitis. J. Leukoc. Biol. 90:483–92.CrossRefGoogle Scholar
  16. 16.
    Rizzo A, et al. (2012) Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages. Inflamm. Bowel Dis. 18:449–59.CrossRefGoogle Scholar
  17. 17.
    Anderson P, et al. (2013) Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis. Gut. 62:1131–41.CrossRefGoogle Scholar
  18. 18.
    Leung G, Wang A, Fernando M, Phan VC, McKay DM. (2013) Bone marrow-derived alternatively activated macrophages reduce colitis without promoting fibrosis: participation of IL-10. Am. J. Physiol. Gastrointest. Liver Physiol. 304:G781–92.CrossRefGoogle Scholar
  19. 19.
    Shouval Dror S, et al. (2014) Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity. 40:706–19.CrossRefGoogle Scholar
  20. 20.
    Wang Y, et al. (2007) Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int. 72:290–9.CrossRefGoogle Scholar
  21. 21.
    Parsa R, et al. (2012) Adoptive transfer of immunomodulatory M2 macrophages prevents type 1 diabetes in NOD mice. Diabetes. 61:2881–92.CrossRefGoogle Scholar
  22. 22.
    Weisser SB, et al. (2014) Arginase activity in alternatively activated macrophages protects PI3Kp110S deficient mice from dextran sodium sulfate induced intestinal inflammation. Eur. J. Immunol. 44:3353–67.CrossRefGoogle Scholar
  23. 23.
    Cao Q, et al. (2014) Failed renoprotection by alternatively activated bone marrow macrophages is due to a proliferation-dependent phenotype switch in vivo. Kidney Int. 85:794–806.CrossRefGoogle Scholar
  24. 24.
    Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W. (2002) Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity. 17:629–38.CrossRefGoogle Scholar
  25. 25.
    van Rooijen N, Hendrikx E. (2010) Liposomes for Specific Depletion of Macrophages from Organs and Tissues. In: Liposomes: Methods and Protocols. Weissig V (ed.) Humana Press, New York, pp. 189–203.CrossRefGoogle Scholar
  26. 26.
    Gordon S, Plüddemann A, Martinez Estrada F. (2014) Macrophage heterogeneity in tissues: phenotypic diversity and functions. Immunol. Rev. 262:36–55.CrossRefGoogle Scholar
  27. 27.
    Bhattacharjee A, et al. (2013) IL-4 and IL-13 employ discrete signaling pathways for target gene expression in alternatively activated monocytes/macrophages. Free Radic. Biol. Med. 54:1–16.CrossRefGoogle Scholar
  28. 28.
    Junttila IS, et al. (2008) Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Rα, IL-13Ra1, and yc regulates relative cytokine sensitivity. J. Exp. Med. 205:2595–608.CrossRefGoogle Scholar
  29. 29.
    Marim FM, Silveira TN, Lima DS Jr, Zamboni DS. (2010) A method for generation of bone marrow-derived macrophages from cryopreserved mouse bone marrow cells. PLoS One. 5:e15263.CrossRefGoogle Scholar
  30. 30.
    Reyes JL, et al. (2015) Splenic B cells from Hymenolepis diminuta-infected mice ameliorate colitis independent of T cells and via cooperation with macrophages. J. Immunol. 194:364–78.CrossRefGoogle Scholar
  31. 31.
    Tiemessen MM, et al. (2007) CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc. Natl. Acad. Sci. U. S. A. 104:19446–51.CrossRefGoogle Scholar
  32. 32.
    Schiwon M, et al. (2014) Crosstalk between sentinel and helper macrophages permits neutrophil migration into infected uroepithelium. Cell. 156:456–68.CrossRefGoogle Scholar
  33. 33.
    Leithäuser F, et al. (2006) Foxp3-expressing CD103+ regulatory T cells accumulate in dendritic cell aggregates of the colonic mucosa in murine transfer colitis. Am. J. Pathol. 168:1898–909.CrossRefGoogle Scholar
  34. 34.
    Sala E, et al. (2015) Mesenchymal stem cells reduce colitis in mice via release of TSG6, independently of their localization to the intestine. Gastroenterology. 149:163–176.e120.CrossRefGoogle Scholar
  35. 35.
    Hutchinson JA, et al. (2011) Cutting edge: immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J. Immunol. 187:2072–8.CrossRefGoogle Scholar
  36. 36.
    Castelo-Branco MTL, et al. (2012) Intraperitoneal but not intravenous cryopreserved mesenchymal stromal cells home to the inflamed colon and ameliorate experimental colitis. PLoS One. 7:e33360.CrossRefGoogle Scholar
  37. 37.
    Gonçalves FdC, et al. (2014) Intravenous vs intraperitoneal mesenchymal stem cells administration: what is the best route for treating experimental colitis? World J. Gastroenterol. 20:18228–39.CrossRefGoogle Scholar
  38. 38.
    Luck H, et al. (2015) Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. Cell Metab. 21:527–42.CrossRefGoogle Scholar
  39. 39.
    Picarella D, et al. (1997) Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J. Immunol. 158:2099–106.PubMedGoogle Scholar
  40. 40.
    Strauch UG, et al. (2001) Integrin αE(CD103) β7 mediates adhesion to intestinal microvascular endothelial cell lines via an E-cadher-in-independent interaction. J. Immunol. 166:3506–14.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Authors and Affiliations

  • Gabriella Leung
    • 1
  • Björn Petri
    • 2
  • José Luis Reyes
    • 1
  • Arthur Wang
    • 1
  • Jordan Iannuzzi
    • 1
  • Derek M. McKay
    • 1
  1. 1.Gastrointestinal Research Group, Department of Physiology and Pharmacology, HSC 1877, Snyder Institute for Chronic DiseasesUniversity of CalgaryCalgaryCanada
  2. 2.Mouse Phenomics Resource Laboratory, Department of Microbiology, Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases, Cumming School of MedicineUniversity of CalgaryCalgaryCanada

Personalised recommendations